Loading
institutionsInstitution
UPMC Hillman Cancer Center
UPMC Hillman is Pittsburgh's NCI comprehensive centre; Bernard Fisher ran the NSABP breast trials here, Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus and Merkel cell polyomavirus, and its LAG-3 biology underpins the melanoma drug relatlimab.
Also called: University of Pittsburgh Cancer Institute
Overview
NCI comprehensive since 1990, UPMC Hillman spans western Pennsylvania through UPMC's network. Bernard Fisher led the NSABP from Pittsburgh, proving with B-06 that lumpectomy plus radiation equals mastectomy and with P-1 that tamoxifen prevents breast cancer; NSABP lives on within NRG Oncology. Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus in 1994 and Merkel cell polyomavirus in 2008. Dario Vignali's LAG-3 biology underpins relatlimab, Hassane Zarour and Diwakar Davar showed faecal microbiota transplant can overcome anti-PD-1 resistance in melanoma, and Greg Delgoffe studies T-cell metabolism in tumours. The centre also has a large head and neck cancer immunotherapy programme.
Location
Pittsburgh, PA, US
Type
cancer center · University of Pittsburgh
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#52 · 51 points (0 Newsweek + 15 NCI + 36 from 18 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to UPMC Hillman Cancer Center, including child institutions. 1,078 works · 21,539 citations · 71% open access · 17% clinical trials · 2% reviews.
Oncology works per year
2132022
2642023
2272024
2362025
1382026
Most works
- Jason J. Luke107 works
- John M. Kirkwood88 works
- Diwakar Davar82 works
- Tullia C. Bruno45 works
- Stephen J. Schuster41 works
- Robert L. Ferris41 works
- Yana G. Najjar40 works
- Dan P. Zandberg35 works
- Paolo A. Ascierto34 works
- Georgina V. Long34 works
Most cited
- Breast cancer trials (NSABP heritage)
- Tumour virology
- Melanoma immunotherapy and microbiome
- LAG-3 biology
Jason J. Luke
Director, Cancer Immunotherapeutics Center, UPMC Hillman Cancer Center
MelanomaAdjuvant immunotherapyEarly-phase immunotherapy
Led KEYNOTE-716, which extended adjuvant pembrolizumab to high-risk stage II melanoma.
John M. Kirkwood
Melanoma medical oncologist, UPMC Hillman Cancer Center
Adjuvant therapy for melanomaInterferonImmunotherapy
Pittsburgh melanoma doctor who ran the interferon trials that were the first adjuvant treatment for high-risk melanoma, and later led CheckMate 76K on adjuvant nivolumab for stage II disease.
observationalJournal of Clinical Oncology 2022changed practice198 citations
The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival
The stage shift the pancreatic cancer page quotes (about three in four surveillance-detected cancers at stage I) and the strongest argument for offering surveillance to every germline carrier found by universal testing, which the NHS does not yet do outside research.
real worldGastroenterology 2019273 citations
Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers
It fixed the working numbers for a comprehensive panel in pancreatic cancer: a hit worth acting on in about one patient in six, most of it in repair genes and the KRAS wild-type minority.
real worldJournal of the National Comprehensive Cancer Network 201786 citations
Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma
ALK is the reason young, KRAS wild-type patients should have fusion testing even though the overall rate is one in six hundred.
Similar pages
- InstitutionApollo Hospitals (Apollo Cancer Centres)
Shares CyberKnife robotic radiosurgery, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer.
- PairingCaution: LAG-3 blockade outside active disease
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- TechnologyZAP-X gyroscopic radiosurgery
Shares CyberKnife robotic radiosurgery, Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS).
- InstitutionGeorgetown Lombardi Comprehensive Cancer Center
Shares CyberKnife robotic radiosurgery, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), National Cancer Institute (NIH), HR-positive / HER2-negative breast cancer.
- JournalTumour virus research
Shares Kaposi sarcoma, Merkel cell carcinoma, Head and neck squamous cell carcinoma.
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares Gamma Knife, Stereotactic radiosurgery (Gamma Knife, CyberKnife, linac SRS), National Cancer Institute (NIH), Melanoma.
- PersonHussein A. Tawbi
Shares Relatlimab + nivolumab, LAG-3, Melanoma.
- PersonBernard Fisher
Shares NRG Oncology, Tamoxifen, HR-positive / HER2-negative breast cancer.
cancers
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-EGFR)
Cetuximab · Erbitux
ApprovedFixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)
Relatlimab + nivolumab · Opdualag
ApprovedSmall-molecule SERM
Tamoxifen · Nolvadex
companies
institutions
people
key papers
Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinomaReal-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkersThe Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival